Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,123 stopped studies mapped to Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,123 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | terminated | Jan 24, 2013 | NewLink Genetics Corporation | not stated | Not stated |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated…(CARACTER) | N/A | terminated | Mar 13, 2013 | Amphia Hospital | bad taste of Caphosol - early stop of intake by patients | Other (stated, no rule matched) |
| NCT03574220 | Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung… | Early Phase 1 | withdrawn | Jun 29, 2018 | Case Comprehensive Cancer Center | No accrual - closed by PRMC | Enrollment / accrual |
| NCT03674450 | Lung Heart Rate Variability(HRV) | N/A | withdrawn | Sep 17, 2018 | Abramson Cancer Center at Penn Medicine | This study never enrolled any subjects. It was terminated due to staffing and technology changes. | Enrollment / accrual |
| NCT02452463 | Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in… | Phase 2 | terminated | May 22, 2015 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous… | Phase 1 | withdrawn | Jun 28, 2011 | Mayo Clinic | lack of access to study drug | Other (stated, no rule matched) |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as… | Phase 2 / Phase 3 | terminated | Oct 6, 2016 | SWOG Cancer Research Network | Drug company decided to terminate all sponsored clinical studies involving rilotumumab. | Sponsor / business decision |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent… | Phase 1 | withdrawn | Jan 8, 2009 | University of Maryland, Baltimore | There was no patient accrual nor study activity due to inability to fund PFTs. | Enrollment / accrual |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable -… | Phase 2 | terminated | Jul 2, 2018 | Montefiore Medical Center | Poor accrual | Enrollment / accrual |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | Phase 1 | terminated | Apr 26, 2010 | University of Maryland, Baltimore | Toxicity was not felt to be acceptable for further development. | Safety / toxicity |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic… | Phase 1 | terminated | Jul 9, 2018 | Regeneron Pharmaceuticals | Program reprioritization | Other (stated, no rule matched) |
| NCT01717482 | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | Phase 2 | terminated | Oct 30, 2012 | Mayo Clinic | Poor accrual and funding ended | Enrollment / accrual |
| NCT03198117 | Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small… | N/A | terminated | Jun 23, 2017 | Qidong Gaitianli Medicines Co., Ltd | Difficulty in patient recruitment | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT03460678 | Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of… | Phase 4 | terminated | Mar 9, 2018 | Hikma Pharmaceuticals LLC | Difficulty recruiting | Enrollment / accrual |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab,…(iTRAP) | Phase 1 | withdrawn | Apr 13, 2018 | Queen Mary University of London | Funder and IMP manufacturer withdrew support | Drug supply |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared… | Phase 1 | terminated | Jun 11, 2015 | Novartis Pharmaceuticals | Major challenge for enrollment of participants. | Enrollment / accrual |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For… | Phase 2 | terminated | Jun 11, 2015 | howard safran | Lack of accrual | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Phase 2 | terminated | Apr 17, 2014 | Heat Biologics | Sponsor Decision; strategic - based on changing treatment landscape | Sponsor / business decision |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell… | Phase 1 | withdrawn | Mar 28, 2013 | Acrotech Biopharma Inc. | not stated | Not stated |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung… | Early Phase 1 | terminated | Oct 16, 2012 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | — | terminated | Apr 10, 2012 | Addario Lung Cancer Medical Institute | interim assessment by sponsor | Other (stated, no rule matched) |
| NCT03872440 | PDX Models From EGFR Mutant Tumors | — | withdrawn | Mar 13, 2019 | Addario Lung Cancer Medical Institute | Did not meet the expected enrollment rate. | Enrollment / accrual |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | Phase 1 | terminated | Jul 20, 2010 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT01918761 | Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung… | Phase 1 | terminated | Aug 8, 2013 | Central European Cooperative Oncology Group | poor accrual | Enrollment / accrual |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to… | Phase 1 | terminated | Dec 18, 2013 | Eli Lilly and Company | This trial was terminated early based on the lack of sufficient clinical efficacy observed. | Efficacy / futility |
| NCT03564054 | Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With… | N/A | terminated | Jun 20, 2018 | University of Florida | slow accrual | Enrollment / accrual |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | Early Phase 1 | terminated | Aug 10, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | Sep 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or… | Phase 1 | terminated | Oct 29, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02501707 | Echocardiography for RILI Prediction | — | terminated | Jul 17, 2015 | Maastricht Radiation Oncology | The study is prematurely terminated due to bad inclusion and the fact that examinations are already… | Other (stated, no rule matched) |
| NCT03232892 | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell… | Phase 2 | terminated | Jul 28, 2017 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT00923273 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure - investigator left the National Institutes of Health. | Investigator |
| NCT02770014 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | Phase 2 | terminated | May 12, 2016 | Dana-Farber Cancer Institute | Terminated due to Osimertinib approval | Other (stated, no rule matched) |
| NCT03529084 | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally… | Phase 3 | withdrawn | May 18, 2018 | Novartis Pharmaceuticals | Decision by Sponsor not to continue with the trial. | Other (stated, no rule matched) |
| NCT02356991 | A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung… | Phase 2 | suspended | Feb 6, 2015 | Jiangsu HengRui Medicine Co., Ltd. | sponsor decides to suspend this trial | Other (stated, no rule matched) |
| NCT02538432 | Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid… | Phase 2 | withdrawn | Sep 2, 2015 | University of Maryland, Baltimore | PI No Longer at University of Maryland. Now at Fox Chase | Other (stated, no rule matched) |
| NCT03272971 | Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors | N/A | terminated | Sep 6, 2017 | Broncus Medical Inc | Lack of enrollment | Enrollment / accrual |
| NCT02448251 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small… | Phase 1 | terminated | May 19, 2015 | ACEA Therapeutics, Inc. | not stated | Not stated |
| NCT03311672 | T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | Phase 2 | withdrawn | Oct 17, 2017 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT02920450 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC… | Phase 1 / Phase 2 | terminated | Sep 30, 2016 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | Phase 1 | withdrawn | Jun 11, 2019 | Muhammad Furqan | Sponsor decision to withdraw | Sponsor / business decision |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02002052 | Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized,…(FLAIR) | Phase 2 | terminated | Dec 5, 2013 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Insufficient accrual | Enrollment / accrual |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With… | Phase 1 | terminated | Mar 17, 2016 | Novartis Pharmaceuticals | considering the limited clinical activity observed with LTT462, the decision was made to not open… | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild…(EGF) | Phase 3 | terminated | Jul 11, 2014 | Bioven Europe | Sponsor decision based on slow recruitment and new emerging drug combinations | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 28, 2020source: clinicaltrials